Locations:
SearchAdvertisement
Dose-finding trial adds to evidence of efficacy
Four genomic clusters identified
A major advance in prognosis for myelodysplastic syndromes that may improve outcomes
Molecular markers could potentially predict major adverse side effects
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Dr. Mikkael Sekeres in his latest New York Times column
Emerging multidisciplinary program seeks better care, outcomes
Sones award honoree advancing knowledge in leukemia, bone marrow failure syndromes
Promising phase 2 study results
What the cancer clinician and researcher need to know
Guideline panel chair shares critical insights
Advertisement
Advertisement